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Context: Globally, one in five men aged .50 years is predicted to experience an osteoporotic
fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming agents for
men, new osteoporosis treatments are needed.
Objective: To evaluate the safety and efficacy of romosozumab in men with osteoporosis.
Design: Phase III randomized BRIDGE study (placebo-controlled double-blind study evaluating the
efficacy and safety of romosozumab in treating men with osteoporosis; ClinicalTrials.gov identifier,
NCT02186171) for 12 months.
Setting: Thirty-one centers in Europe, Latin America, Japan, and North America.
Patients:Men aged 55 to 90 years with a baseline bonemineral density (BMD) T-score at the lumbar
spine (LS), total hip (TH), or femoral neck of #22.5 or #21.5 with a history of a fragility non-
vertebral or vertebral fracture.
Interventions: The subjects were randomized 2:1 to receive romosozumab 210 mg subcutaneously
monthly or placebo for 12 months.
MainOutcomeMeasures: The primary efficacy endpoint was percentage change frombaseline in LS
BMD at month 12.
Results: In 245 subjects (163 romosozumab, 82 placebo), at month 12, the mean percentage change
from baseline in the LS and TH BMDwas significantly greater for the romosozumab group than for
the placebo group (LS, 12.1% vs 1.2%; TH, 2.5% vs 20.5%; P , 0.001). Adverse events and serious
adverse events were balanced between the two groups, with a numerical imbalance in the pos-
itively adjudicated cardiovascular serious adverse events [romosozumab, 8 (4.9%) vs placebo,
2 (2.5%)].
Conclusions: Treatment with romosozumab for 12 months increased the spine and hip BMD
compared with placebo and was well tolerated in men with osteoporosis. (J Clin Endocrinol Metab
103: 3183–3193, 2018)
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Osteoporosis affects 1 to 2 million men in the UnitedStates and 5.5 million men in the European Union,
with 8 to 13 million men in the United States having
osteopenia (1, 2). One in three fractures occur in men
aged.60 years, with a lifetime osteoporosis fracture risk
of 15%. The morbidity and mortality associated with
fracture, in particular hip fracture, are greater for men
than for women (3–5). Globally, the fracture incidence is
expected to increase owing to the aging population (6).
According to the Endocrine Society clinical practice
guideline, pharmacological treatment is recommended
for men aged.50 years who have experienced a spine or
hip fracture, those with a T-score of #22.5, and those
with a high risk of fracture because of low bone mineral
density (BMD) and/or clinical risk factors (7). Because of
the large osteoporosis treatment gap (8), which is worse
for men than for women (9), and because idiopathic male
osteoporosis might have low bone turnover (10), a need
exists for new strategies to improve osteoporosis care and
for new treatment options for male osteoporosis, espe-
cially bone-forming agents.
Romosozumab is a humanized monoclonal antibody
that binds and inhibits sclerostin. Sclerostin, which is
secreted by osteocytes, has been shown to regulate bone
formation. Inhibition of sclerostin by romosozumab
is characterized by a dual effect—increasing bone formation
and decreasing bone resorption (11, 12). Romosozumab
has shown efficacy in the treatment of postmenopausal
women with a low bone mass in a phase II study (11) and
women with osteoporosis in a phase III study [FRAME
(efficacy and safety of romosozumab treatment in post-
menopausal women with osteoporosis)] (13). In FRAME,
romosozumab treatment for 12 months was associated
with a substantially greater increase from the baseline BMD
at the lumbar spine (LS), total hip (TH), and femoral neck
(FN), a significantly lower incidence of vertebral and clinical
(nonvertebral plus symptomatic vertebral) fractures, and a
numerically lower incidence of nonvertebral fractures
compared with placebo (13). The present study evaluated
the safety and efficacy of romosozumab in men with
osteoporosis. This was a bridging study to extrapolate
the fracture benefit observed in women with osteopo-
rosis in FRAME to men by demonstrating that the BMD
profile in the male population is comparable to that in the
female population.
Materials and Methods
Study design
We performed a phase III BRIDGE study (placebo-controlled
study evaluating the efficacy and safety of romosozumab in
treating men with osteoporosis; ClinicalTrials.gov identifier,
NCT02186171). Eligible subjectswere randomized 2:1 to receive
romosozumab 210 mg subcutaneously once a month (QM) or
matched placebo for 12months, with 500 to 1000 mg of calcium
and 600 to 800 IU of vitamin D daily (Supplemental Fig. 1).
Randomization was stratified by geographic region (Europe,
NorthAmerica, LatinAmerica, and Japan). On completion of the
12-month treatment period, the subjects were followed up for an
additional 3 months to evaluate the development of antibodies
against romosozumab. Additional study details are available at
EudraCT and ClinicalTrials.gov. The dosing strategy was
modeled after that used in FRAME. Two phase I studies of men
and women provided evidence of comparability between males
and females in the pharmacokinetics of romosozumab (12, 14).
Study population
The key inclusion criteria were men aged 55 to 90 years;
dual-energy X-ray absorptiometry (DXA) BMD T-score at the
LS, TH, or FN of #–2.5 or #–1.5 with a history of fragility
nonvertebral or vertebral fracture; and two or more vertebrae
(L1 to L4) and one or more hip evaluable for DXA assessment.
The key exclusion criteria were a T-score at the TH or FN
of#–3.5, a history of hip fracture, the presence of metabolic or
bone diseases or substantial laboratory abnormalities, or the
current use of a medication affecting the bone metabolism
(including oral and intravenous bisphosphonates, teriparatide,
or any PTH analogs, and denosumab). The full exclusion cri-
teria can be found in the Supplemental Materials.
Copies of the protocol and informed consent form were
submitted to the independent ethics committee or institutional
review board at each center for written approval. The present
study was conducted in accordance with International Con-
ference on Harmonization Good Clinical Practice and appli-
cable regulatory requirements. All participants provided
written informed consent before inclusion in the study.
Randomization and blinding
Randomization and the determination of treatment as-
signments occurred after all screening procedures had been
performed and the subjects had met all the eligibility criteria.
The subjects were randomized to the treatment assignment in a
double-blind manner. Randomization, using a schedule pre-
pared by the Amgen Central Randomization Group before the
start of the study, was performed using an interactive voice
response system. A subject’s treatment assignment could be
unblinded only when knowledge of the treatment was essential
for further treatment of that patient during the present study.
Sample size considerations
The sample size was calculated using a two-sided, two-
sample t test with a 5% significance level for the comparison
of romosozumab with placebo by percentage change from
baseline in the LS, TH, and FN BMD by DXA at month 12. A
sample size of 225 subjects (150 romosozumab and 75 placebo)
was expected to provide.99% power to assess the superiority
for the LS, TH, and FN BMD changes at month 12, assuming a
10.0%, 4.0%, and 3.7% difference between romosozumab and
placebo, respectively. This would also allow analysis of the
safety and tolerability of romosozumab in men with osteopo-
rosis. In addition, the present study used a 2:1 randomization of
romosozumab to placebo subjects based on the recommenda-
tion of the Food and Drug Administration to expose $150
subjects to romosozumab, combined with the consideration of
limiting the number of subjects exposed to placebo.
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Objectives
The primary objective of the present study was to evaluate
the effect of treatment with romosozumab for 12 months
compared with placebo on percentage change from baseline in
the LS BMD as assessed by DXA in men with osteoporosis. The
secondary objectives were to evaluate the effect of treatment
with romosozumab compared with placebo on percentage
change from baseline in (1) TH and FN BMD at 12 months
and (2) LS, TH, and FN BMD at 6 months. The explor-
atory objectives were to evaluate the effect of treatment with
romosozumab for 12 months compared with placebo on (1)
the percentage change from baseline in the serum bone for-
mation marker procollagen type 1 N-terminal propeptide
(P1NP) and bone resorption marker C-telopeptide of type 1
collagen (CTX) and (2) the bone histologic findings and his-
tomorphometry (15) in a bone biopsy substudy of a subset of
subjects. The safety objective was to characterize the (1) safety
and tolerability of treatment with romosozumab for 12 months
compared with placebo, as determined by adverse events re-
ported by the trial-site physicians, and (2) formation of anti-
romosozumab antibodies during the 15-month trial period
(12 months of treatment plus 3 months of follow-up). Poten-
tial cardiovascular-related serious adverse events, including
deaths, and potential cases of osteonecrosis of the jaw and
atypical femoral fracture were identified using predefined
search strategies and adjudicated by their respective indepen-
dent adjudication committees.
Outcome measures
BMD measurements were performed by DXA (GE Lunar,
Madison, WI, or Hologic Inc., Marlborough, MA); the same
instrument was used for all study procedures for a particular
subject for the duration of the study. All DXA scans were
submitted to and analyzed by a central imaging vendor (Synarc,
Newark, CA), which provided instructions for the acquisition
of bone scans. Quality control of DXA instruments included a
completed quality assurance spine phantom form listing 25
most recent spine phantom scans and the calculated acceptable
range. Cross-calibration used 20 volunteers scanned on old and
upgraded systems and between two scanners at the relevant
skeletal sites. BMD was measured at the LS and proximal fe-
mur. All T-scores were determined using reference data for
whites and the mean BMD for a young, healthy, sex-matched
adult population. Blood samples for evaluating bone turnover
markers (BTMs) and anti-romosozumab antibodies were
processed by a central laboratory and sent to an appropriate
secondary laboratory or the study sponsor for analysis or
distributed further to other laboratories. Additional informa-
tion on anti-romosozumab antibodies is available in the Sup-
plemental Materials. A subset of subjects underwent a transiliac
crest bone biopsy at month 12; the methods are available in the
Supplemental Materials.
Statistical analysis
Analysis of the primary efficacy endpoint of percentage
change from baseline in the LS BMD at month 12 was con-
ducted for subjects with a baseline and at least one postbaseline
LS BMD measurement. An analysis of covariance (ANCOVA)
model with last observation carried forward imputation was
used. The ANCOVA model included treatment, baseline DXA
BMD value, baseline testosterone level, and the stratification
factor of geographic region (Europe, North America, Latin
America, or Japan) as the main effects. Additional covariates of
machine type (Hologic or GE Lunar) and machine type-by-
baseline DXA BMD value interaction were included in the
model to adjust for the effect of machine type on the baseline
DXA BMD value. Summaries for the results included least
squares mean point estimates of percentage change from
baseline for each treatment arm. The two-sided 95% CI and
associated P valuewere computed for the difference between the
least squares means for romosozumab and placebo. A similar
model was used for the primary efficacy endpoint stratified by
subgroup: baseline testosterone level (,250 vs $250 ng/dL),
baseline minimum T-score (#22.5 vs .22.5; minimum was
defined as the lower value of the baseline BMD LS or FN
T-score), baseline age (,70 vs$70 years), and baseline 10-year
major osteoporotic fracture risk (less than the median vs the
median or greater; the median was 7.62 for the overall study
population). All subgroup analyses were post hoc analyses. In
addition, percentage change from baseline in the TH and FN
BMD at month 12 was evaluated by age subgroup (,70
vs $70 years).
For each secondary efficacy BMD endpoint, the percentage
change from baseline in the DXA BMD used an ANCOVA
model similar to that for the primary efficacy endpoint. The
secondary efficacy endpoint hypotheses of different efficacy of
romosozumab compared with placebo were tested, and the
significance levels were adjusted using Hochberg method-
ology, using two-sided comparisons at an initial signifi-
cance level of 0.05 for LS BMD at month 6 and FN and TH
BMD at months 6 and 12. The analyses included subjects who
had a baseline and at least one postbaseline DXA BMD
measurement at the corresponding skeletal site. To control for
multiplicity for assessment of the primary and secondary
endpoints, a combination of hierarchical andHochberg testing
procedures was implemented.
For the exploratory endpoints assessing serum P1NP and
CTX levels, descriptive statistics are presented stratified by
treatment group at each visit for the absolute and percentage
change from the baseline value. Graphs depicting the median
and interquartile range by treatment group for percentage
change over time are provided. The significance of the treatment
difference for percentage change from baseline at each visit was
assessed using a Van Elteren rank-sum test, adjusting for region
as the stratification factor.
For the bone biopsy substudy, the bone histologic fea-
tures and histomorphometry parameters are summarized de-
scriptively. Cross-sectional evaluation of the histomorphometry
parameters at month 12 was performed between treat-
ment groups using the Wilcoxon rank-sum test to test for
statistical significance.
For the 12-month treatment period, the subject incidence of
all treatment-emergent adverse events was tabulated by system
organ class and the preferred term coded by the Medical
Dictionary for Regulatory Activities, version 18.1, for all
subjects who had received at least one dose of the in-
vestigational product. Tabular data of the fatal adverse
events, serious adverse events, adverse events leading to
withdrawal from the investigational product, and events of
interest are provided. The incidence and percentage of sub-
jects who developed anti-romosozumab antibodies (binding
and, if positive, neutralizing) at months 1, 3, 6, and 12 were
tabulated stratified by treatment group. The analysis was
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repeated to include all results from the samples collected
during the 3-month follow-up period.
Results
Subject disposition
A total of 245 subjectswere enrolled in the present study;
163 were randomized to receive romosozumab 210 mg
QM and 82 to placebo QM for 12 months (Table 1). The
first subject was enrolled on 16 June 2014. The data cutoff
date for the 12-month primary analysis was 27 January
2016. The subject disposition is shown in Fig. 1. The
baseline demographic and disease characteristics were
balanced between the two groups. Overall, the mean6 SD
age was 72.1 6 7.3 years, with 40.4% of subjects
aged .75 years at enrollment. The mean body mass index
was 25.16 3.9 kg/m2. The baseline T-scores were22.36
1.3 at the LS,21.96 0.6 at the TH, and22.36 0.5 at the
FN. The regional distribution of the subjects was 66.1% in
Europe, 14.3% in Latin America, 11.0% in Japan, and
Table 1. Baseline Characteristics
Characteristic Romosozumab 210 mg QM (N = 163) Placebo (N = 82)
Age, y 72.4 6 7.4 71.5 (6.9)
Age ,75 y, n (%) 93 (57.1) 53 (64.6)
Age $75 y, n (%) 70 (42.9) 29 (35.4)
BMD T-score
LS 22.22 6 1.19 22.33 6 1.41
TH 21.92 6 0.59 21.92 6 0.65
FN 22.34 6 0.52 22.30 6 0.52
Serum P1NP, mg/L, median (IQR) 48.0 (33.6–59.7) 45.2 (34.3–57.9)
Serum CTX, ng/L, median (IQR) 346 (239–483) 350 (231–498)
Previous fracture,a n (%) 86 (52.8) 46 (56.1)
FRAX score with BMDb
Major osteoporotic fracture 9.0 6 5.2 8.6 6 5.2
Major osteoporotic fracture, median (IQR) 7.7 (5.6–11.7) 7.2 (4.7–12.6)
Hip fracture 4.0 6 3.3 3.6 6 2.6
Hip fracture, median (IQR) 3.3 (1.8–4.9) 3.0 (1.6–4.8)
Previous osteoporosis medication, n (%)
Oral bisphosphonate 1 (0.6) 5 (6.1)
PTH or PTH derivative 1 (0.6) 0 (0.0)
Calcitonin 2 (1.2) 2 (2.4)
Strontium ranelate 1 (0.6) 0 (0.0)
Fluoride 0 (0.0) 0 (0.0)
Calcitriol 5 (3.1) 2 (2.4)
Denosumab 3 (1.8) 3 (3.7)
History of smoking, n (%)
Never 82 (50.3) 31 (37.8)
Former 54 (33.1) 34 (41.5)
Current 27 (16.6) 17 (20.7)
Cardiovascular risk factors,c n (%) 126 (77.3) 59 (72.0)
History of diabetes 55 (33.7) 33 (40.2)
History of hypertension 83 (50.9) 44 (53.7)
History of hypercholesterolemia 63 (38.7) 33 (40.2)
History of cardiovascular disease 108 (66.3) 54 (65.9)
History of central nervous system vascular disorder 15 (9.2) 10 (12.2)
Total testosterone, n (%)
,250 ng/dL 39 (23.9) 14 (17.1)
$250 ng/dL 123 (75.5) 68 (82.9)
Creatinine, mmol/L 88.3 (15.8) 90.8 (19.1)
25-hydroxyvitamin D, ng/mL 28.4 (8.9) 27.3 (6.7)
Data presented as mean 6 SD, unless otherwise noted.
Abbreviations: FRAX, fracture risk assessment tool; IQR, interquartile range; N, number of subjects randomized.
aIncluded all vertebral fractures and nonvertebral fractures after 45 y of age.
bThe score using the FRAX (16), developed by the World Health Organization (available at: www.shef.ac.uk/frax/) indicates the 10-y risk of a major
osteoporotic fracture and hip fracture calculated with the BMD.
cA history of cardiovascular risk factors was assessed using the medical history electronic case report form relating to a history of diabetes, hypertension,
hypercholesterolemia, cardiac disorder, vascular disorder, and central nervous system vascular disorders (high level group term in the Medical Dictionary
for Regulatory Activities, version 18.1); the subjects could have more than one cardiovascular risk factor; therefore, subject incidence rates might not sum
to the total.
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8.6% in North America. Of the 245 subjects, 73.5% were
white, 11.0% were Asian, and 14.7% were “other.” The
romosozumab and placebo groups had a similar fracture
risk (53% and 56% had a previous fracture, respectively),
a similar FRAX (fracture risk assessment tool) with BMD
10-year fracture probability of a major osteoporotic
fracture (clinical spine, hip, shoulder, and forearm; 9.0%
and 8.6%, respectively), and a similar 10-year fracture
probability of a hip fracture (4.0% and 3.6%, respectively).
Efficacy
After 12 months, the subjects receiving romosozumab
had had a significantly greater mean increase from
baseline in the LS BMD compared with the subjects
receiving placebo (12.1% vs 1.2%; P , 0.001). Those
receiving romosozumab also had significantly greater
mean BMD increases from baseline (vs placebo) at
the TH (2.5% vs 20.5%; P , 0.001) and FN (2.2%
vs 20.2%; P , 0.001) at month 12 (Fig. 2). Statistically
significant differences in LS, TH, and FN BMD were
observed between the romosozumab and placebo groups
as early as month 6 (LS, 9% vs 0.3%; and TH, 1.6% vs
0.2%; P , 0.001; FN, 1.2% vs 0.0%; P = 0.0033).
The percentage change from baseline in LS BMD at
month 12 was evaluated by the baseline subgroups
specified in the Statistical analysis section. The treatment
effect of romosozumab vs placebo in the percentage
change from baseline in LS BMD at month 12 was
consistent for all subgroups assessed (Fig. 3). Although
the P value for the treatment by subgroup interaction was
statistically significant for testosterone level, no quali-
tative difference was found in the LS BMD change from
baseline between the two subgroups. The subgroup of
subjects with a testosterone level ,250 ng/dL was rel-
atively small; however, the difference in the percentage
change from baseline in the LS BMD at 12 months be-
tween the romosozumab and placebo subgroups was
still substantial. In addition, the treatment effect
of romosozumab vs placebo in the mean percentage
change from baseline in TH and FN BMD at month
12 was similar between the age subgroups: 2.6% for
romosozumab vs 21.1 for placebo for age ,70 years
and 2.5% for romosozumab vs 20.3% for placebo for
age $70 years at the TH and 2.6% for romosozumab
vs 0.2% for placebo for age ,70 years and 2.1% for
romosozumab vs20.5% for placebo for age$70 years
at the FN.
As part of an exploratory objective, the percent-
age change from baseline in serum BTMs during the
12-month period was assessed. The P1NP levels in-
creased early in subjects receiving romosozumab, peak-
ing at month 1, when the median percentage change from
baseline was 85.8% compared with 1.2% in the placebo
group (P , 0.001; Fig. 4). By month 3, the median
percentage change from baseline was 25.4% in the
romosozumab group and 22.4% in the placebo group
(P , 0.001). The median percentage change from base-
line through the end of the study was20.9% and22.5%
at month 6 (P = 0.58) and 219.7% and 26.2% at
month 12 (P = 0.0032) for romosozumab and placebo,
Figure 1. Consolidating standards of reporting trials diagram of BRIDGE showing flow of subjects screened for the study through week 12. IP,
investigational product.
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respectively. The CTX levels also changed early in the study
in the subjects receiving romosozumab, with the greatest
decrease at month 1, when the median change from
baseline was 230.8% compared with 21.7% in those
receiving placebo (P, 0.001; Fig. 4). The CTX levels in the
romosozumab group remained less than those in the pla-
cebo group throughout the study: 216.8% vs 28.2%
at month 3 (P = 0.15), 224.2% vs 25.8% at month 6
(P,0.001), and227.8%vs0.7%atmonth 12 (P,0.001).
Bone biopsy substudy
Twenty subjects (n = 11, romosozu-
mab; n = 9, placebo) were enrolled in the
bone biopsy substudy. Histomorpho-
metric analyses at 12 months showed a
reduction in bone resorption consistent
with that previously observed in post-
menopausal women with osteoporosis
(Supplemental Materials).
Safety
The incidence rate of treatment-
emergent adverse events was 75.5%
in the romosozumab group and 80.2%
in the placebo group (Table 2). Over-
all, 12.9% of the romosozumab group
and 12.3% of the placebo group
experienced a serious adverse event,
and 3.1% and 1.2% experienced an
adverse event leading to discontinua-
tion of the investigational product,
respectively. Incident fractures were
reported in three subjects (1.8%) in the
romosozumab group and two subjects
(2.5%) in the placebo group. Injection-
site reactions were reported for 5.5%
of the subjects in the romosozumab
group and 3.7% in the placebo group.
The injection-site reactions reported
in more than one subject included
injection-site pain (n = 4) and injection-
site erythema (n = 3) in the romosozu-
mab group and injection-site pruritus
(n = 2) in the placebo group. A nu-
merical difference was found in the
overall positively adjudicated cardio-
vascular serious adverse events be-
tween the romosozumab and placebo
groups [8 (4.9%) vs 2 (2.5%), re-
spectively; Table 2]. These included
cardiac ischemic events [3 (1.8%) vs
0 (0.0%)], cerebrovascular events
[3 (1.8%) vs 1 (1.2%)], and heart
failure events [1 (0.6%) vs 0 (0.0%)]
in the romosozumab and placebo groups, respectively
(Table 2). In addition, one positively adjudicated car-
diovascular death occurred in each treatment group
through month 12 [0.6%, romosozumab (cardiore-
spiratory arrest); 1.2%, placebo (sudden death)].
During the 3-month follow-up period (months 12 to
15), one additional positively adjudicated cardiovas-
cular death (unknown cause), which occurred in the
first 12 months of the study, was reported for a subject
Figure 2. Percentage change from baseline in BMD stratified by visit. Percentage change
from baseline in (a) LS, (b) TH, and (c) FN BMD stratified by visit. Data presented as least
squares mean estimates with 95% CIs. *P , 0.001 vs placebo; †P = 0.0033. N, all
randomized subjects with a baseline and one or more postbaseline measurements; n,
number of subjects with values at baseline and at or before the time point of interest.
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in the romosozumab group. That subject had previ-
ously had a positively adjudicated cardiovascular event
(myocardial ischemia). Of the 10 subjects with posi-
tively adjudicated cardiovascular serious adverse events,
all 8 in the romosozumab group and 1 of 2 in the
placebo group had baseline cardiovascular risk factors.
Two of the eight subjects in the romosozumab group
and one of the two subjects in the placebo group with a
positively adjudicated cardiovascular serious adverse
event had positive findings in their cardiovascular med-
ical history and were not taking cardioprotective drugs
before the start of the present study. Overall, 126 sub-
jects (77.3%) in the romosozumab group and 58 (71.6%)
in the placebo group had positive findings in their
cardiovascular-related medical history. Of these subjects,
93 (57.1%) in the romosozumab group and 50 (61.7%)
in the placebo group had a baseline use of cardiovascular-
related concomitant medications. No positively adjudi-
cated cases of atypical femoral fracture or osteonecrosis
of the jaw were reported.
Through month 15, all 163 subjects (100%)
who received romosozumab had an on-study anti-
romosozumab antibody test result. Of the 162 subjects
with a postbaseline result, 28 (17.3%) had binding an-
tibodies and 1 (0.6%) had neutralizing antibodies at any
postbaseline visit through month 12 (Table 2). No
subjects had binding antibodies at month 1. The per-
centage of subjects with binding antibodies at months 3,
6, and 12 was 4.4%, 16.9%, and 13.2%, respectively.
During the 3-month follow up period, one subject who
was positive for binding antibodies at month 12 tested
positive for neutralizing antibodies at month 15. During
the 15-month trial period, 35 subjects (19.6%) in the
romosozumab group developed anti-romosozumab an-
tibodies, 1 (0.6%) of whom had neutralizing antibodies.
Anti-romosozumab antibodies had no detectable ef-
fect on efficacy or safety, because the percentage
change in BMD at the lumbar spine from baseline to
month 12 was similar in those with and without anti-
romosozumab antibodies (12.6 and 12.8, respectively;
Supplemental Table 1).
Discussion
In the present study of men with osteoporosis, romo-
sozumab treatment for 12 months resulted in rapid and
substantial BMD gains at the LS, TH, and FN compared
with placebo. Evaluation of the BTMs showed early
increases in bone formation and decreases in bone re-
sorption in the subjects treated with romosozumab
compared with placebo. Romosozumab was generally
well tolerated. The overall subject incidence of ad-
verse events (75.5% and 80.2%, respectively) and seri-
ous adverse events (12.9% and 12.3%, respectively)
was comparable between the romosozumab and pla-
cebo groups. Although small numerical differences were
observed in the positively adjudicated cardiovascular
serious adverse events, more subjects with positively
adjudicated cardiovascular serious adverse events and
positive findings in their cardiovascular disease history
were in the romosozumab group than in the placebo
group. Among the subjects with positive findings in their
cardiovascular disease history, the romosozumab group
had fewer subjects using cardioprotective medications at
baseline compared with the placebo group. Based on the
subgroup analyses, romosozumab is effective for the
treatment of a spectrum of men with osteoporosis, in-
cluding those with hypogonadism.
Osteoporosis therapies have been studied extensively
in women and to a lesser extent in men. Even in the
Figure 3. LS BMD by DXA percentage change from baseline to month 12 stratified by baseline subgroups. ANCOVA model adjusted for
treatment, baseline DXA BMD, machine type, baseline testosterone level, geographic region (stratification factor), and machine type-by-baseline
DXA BMD and using a variance structure allowing for heterogeneity between treatment groups. Minimum baseline BMD T-score was defined as
the lower value of the LS and FN BMD T-scores. aMedian baseline 10-year major osteoporotic fracture risk was 7.62 for the overall study
population. N, number of subjects with a baseline and at least one postbaseline LS BMD measurement; SC, subcutaneously.
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studies of men, most outcome measures have included
BMD and BTMs as surrogates for fracture efficacy,
with no fracture endpoints, especially hip and non-
vertebral fractures (17). Previous studies of men have
included treatment with the bisphosphonates alendro-
nate, risedronate, and zoledronic acid; denosumab;
and teriparatide. All therapies have been shown to in-
crease the BMD (18–25). Studies showing a reduction
in vertebral fractures with alendronate, risedronate,
zoledronic acid, denosumab, and teriparatide have been
more limited and were not powered or
designed to demonstrate antifracture
efficacy, in particular for nonvertebral
and hip fractures (19, 21, 24, 25).
In contrast to other approved agents
for the treatment of male osteoporosis,
teriparatide is an anabolic agent that
has been shown to promote bone forma-
tion. Previous studies have demonstrated
that teriparatide treatment increases bone
remodeling, with increases in bone for-
mation markers preceding increases in
bone resorption markers, indicating a
transient increase in modeling-based for-
mation (10, 23, 26). Teriparatide treatment
also results in substantial increases in BMD
at the LS and FN compared with placebo
(10, 23). In a substudy of a phase II clinical
trial of postmenopausal women with a
low bone mass, romosozumab 210 mg
QM for 12 months resulted in significantly
greater increases in both vertebral and
femoral strength compared with teripara-
tide 20 mg daily (27). Finite element ana-
lyses of quantitative computed tomography
scans at the spine and hip have shown that
increases in bone strength at the spine can
be attributed to increases in both corti-
cal and trabecular compartments for both
romosozumab and teriparatide treatment.
However, increases in bone strength at
the hip were attributed to both cortical
and trabecular compartments for romo-
sozumab compared with nonsubstantial
changes in cortical and trabecular com-
partments for teriparatide (27). These
data were further confirmed in a phase III
trial of postmenopausal women tran-
sitioning from oral bisphosphonates to
romosozumab 210 QM or teriparatide
20 mg daily (28). Similar to studies of
other osteoporosis agents, a paucity of
studies has described the effect of ter-
iparatide on fractures in men. The prescribing in-
formation for teriparatide noted the occurrence of
dose- and time-dependent risk of osteosarcoma in rats
exposed to teriparatide (29, 30). However, this has not
been observed in clinical trials or postmarketing
studies (31, 32).
The rapid onset of treatment effect with romosozumab
might provide protection to patients during the early
stages of treatment. Subjects receiving romosozumab had
attained a significantly greater BMD gain from baseline
Figure 4. Percentage change from baseline in BTMs stratified by visit. Percentage change
from baseline in (a) serum P1NP and (b) serum CTX levels stratified by visit. Data presented
as median and interquartile range. *P , 0.001 vs placebo. N, all randomized subjects with
a baseline and at least one postbaseline measurement; n, number of subjects with values at
baseline and at the time point of interest.
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by month 6 at the LS, TH, and FN and a statistically
significant increase in P1NP and reduction in CTX by
month 1 compared with subjects receiving placebo. The
rapid onset of treatment benefits in this patient pop-
ulation has become increasingly important, because the
risk of fracture increases after the occurrence of a frac-
ture, especially the imminent risk within 1 year of the
previous fracture (33–35).
In the bone biopsy specimens collected at month 12,
all samples evaluable for histologic examination showed
normal lamellar bone and normal mineralization. At
month 12, the parameters of bone resorption had de-
creased and those of bone formation were unchanged in
the romosozumab group compared with the placebo
group. These results are consistent with the BTM results
observed at month 12 (Fig. 4).
The BMD and BTM results in the present trial were
consistent with those in postmenopausal women in
FRAME. FRAME demonstrated that romosozumab
treatment in women results in improvements in BMD,
changes in BTMs, and reductions in vertebral and clinical
fractures (13). The increases in BMD and changes in
BTMs observed were similar to those observed in the
present study (BRIDGE). In addition, the populations in
BRIDGE and FRAME had a similar risk of fracture using
the 10-year probability of major osteoporotic fracture by
FRAX (Supplemental Fig. 2). Romosozumab also had a
similar pharmacodynamic effect in men and women, as
shown by the similar patterns of, timing of, and quan-
titative changes in the BTMs. Based on the observed
BMD gains and similar fracture risk in this bridging
study, the fracture reduction benefit observed in FRAME
can be extrapolated to male patients with osteoporosis.
This suggests that romosozumab treatment could also
reduce fractures in men with osteoporosis, although a
romosozumab antifracture study has not been performed
in men, similar to what has been reported in previous
bridging studies for alendronate and denosumab (21, 36,
37). Although the subjects in BRIDGE and FRAME had
slightly different osteoporosis severity, based on the
baseline minimum T-score, the subgroup analyses in
BRIDGE have indicated that romosozumab is effective
across a broad range of osteoporosis severity as assessed
by the baseline BMD T-scores (Fig. 3). The pharmacoki-
netic analysis results were also similar in men and women
through 12 months of treatment with romosozumab
210 mg QM, with exposure reaching a steady state at
3 months for both men and women.
Conclusions
In BRIDGE, treatment with romosozumab 210 mg
subcutaneously QM increased the spine and hip BMD
compared with placebo at months 6 and 12 and was well
tolerated in men with osteoporosis. Romosozumab,
which has a dual effect of increasing bone formation and
decreasing bone resorption, appears to be a new and
promising bone-forming treatment for men with osteopo-
rosis. This dual effect is a unique aspect of romosozumab
that has not been observed with any other agent approved
for the treatment of osteoporosis.
Table 2. Summary of Subject Incidence of
Treatment-Emergent Adverse Events Through
Month 12
Adverse event, n (%)
Romosozumab
210 mg QM
(N = 163)
Placebo
(N = 81)
Any adverse event 123 (75.5) 65 (80.2)
Serious adverse event 21 (12.9) 10 (12.3)
Adjudicated cardiovascular
serious adverse eventa
8b (4.9) 2 (2.5)
Cardiac ischemic event 3 (1.8) 0 (0.0)
Cerebrovascular event 3 (1.8) 1 (1.2)
Deathc,d 2e (1.2) 1 (1.2)
Heart failure 1 (0.6) 0 (0.0)
Death 1 (0.6) 1 (1.2)
Leading to discontinuation of
investigational product
5 (3.1) 1 (1.2)
Events of interest
Hypocalcemia 0 (0.0) 0 (0.0)
Hypersensitivity 8 (4.9) 4 (4.9)
Injection-site reactionf 9 (5.5) 3 (3.7)
Malignancy 3 (1.8) 2 (2.5)
Hyperostosis 0 (0.0) 0 (0.0)
Osteoarthritis 8 (4.9) 4 (4.9)
Atypical femoral fracturea 0 (0.0) 0 (0.0)
Osteonecrosis of the jawa 0 (0.0) 0 (0.0)
Incident fractureg 3 (1.8) 2 (2.5)
Subject incidence of anti-
romosozumab antibody
formation
Binding antibodies 28 (17.2) NA
Neutralizing antibodies 1 (0.6) NA
Abbreviations: NA, not applicable; N, number of subjects who received
one or more dose of investigational product; n, number of subjects with
one or more event.
aOnly included events adjudicated as positive by the independent ad-
judication committee.
bOne subject presented with two cardiovascular serious adverse events.
cAdjudicated cardiovascular death events included fatal events adjudi-
cated as cardiovascular-related or undetermined.
dPositively adjudicated cardiovascular deaths were due to cardiorespi-
ratory arrest (romosozumab), sudden death (placebo), and unknown
cause [romosozumab; occurred during the first y of the study and was
reported during the follow-up period (mos 12 to 15)].
eOne additional subject with a positively adjudicated cardiovascular
serious adverse event experienced a fatal cardiovascular event (unknown
cause) during the primary analysis period (through mo 12), which was
reported after the primary analysis snapshot.
fMost reactions were reported as mild in severity.
gIncident fractures included vertebral and nonvertebral fractures—
upper limb, rib, lumbar vertebral, thoracic vertebral, and humerus
fractures.
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